Proactive Investors - Run By Investors For Investors

WideCells reshuffles boardroom as part of its growth plans

Chairman Peter Presland will take on a more active role to free up more time for CEO João Andrade to focus on sales and business development
CFO David Bridgland will leave the company at the end of 2018

Stem cell treatment insurance provider WideCells Group PLC (LON:WDC) is restructuring its board as part of its plans to minimise costs, refocus its strategy and target revenue growth.

Chief financial officer David Bridgland has stepped down from the board but will serve out his notice period until the end of the year. A non-board financial controller will be recruited in his place.

READ: WideCells secures £2.7mln financing deal as it announces turnaround strategy

Professor Peter Hollands has also stepped down from his board position but will remain as a director of WideCells’ Storage and Research division, as well as the group's chief scientific officer.

Company chairman Peter Presland will take on additional duties until the group has stabilised, overseeing corporate matters, financial management and relationships with investors and advisors.

That will free up chief executive João Andrade to focus more on sales and business development.

“I'd like to thank David for his work with the group and I wish him all the best in his future endeavours,” said Presland.

“Professor Hollands will continue to be an invaluable asset to us as the group's chief scientific officer, and I'd like to extend my special gratitude to him for his work on the board.”

He added: “Moving forward, I'll be taking a more active role in the financial management of the group and additional corporate responsibilities to free up time for our CEO, João Andrade, to focus on what he is really good at - sales and business growth.”

View full WDC profile View Profile

WideCells Group Timeline

Big Picture
April 18 2019

Related Articles

Pictured is the company's myLotus test
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use